Clinical trials update: Tertiary prevention of colorectal cancer

Journal of Carcinogenesis

Volumn 10, Issue , 2011, Pages

  Zell, Jason ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; EFLORNITHINE; FLUOROURACIL; FOLINATE CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; ROSUVASTATIN; SULINDAC;

ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; TREATMENT OUTCOME;

EID: 84863049663     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.78271     Document Type: Article

References (37)

1. Ganz PA. A teachable moment for oncologists: Cancer survivors, 10 million strong and growing! J Clin Oncol 2005;23:5458-60.
2. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007;298:754-64. (Pubitemid 47263158)
3. Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, Gerner EW, et al. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. International Journal of Cancer 2007;120:459-68. (Pubitemid 44969014)
4. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24:3527-34. (Pubitemid 46630522)
5. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 2006;24:3535-41. (Pubitemid 46630523)
6. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92. (Pubitemid 40727085)
7. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007;99:32-40.
8. Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin use and colorectal adenoma risk: Results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2010;3:588-96.
9. American Association for Cancer Research (2010, November 8). Statins fail to reduce colorectal cancer in postmenopausal women, study finds. ScienceDaily. Available from: http://www.sciencedaily.com/releases/2010/11/101108140414.htm. [Last eccessed on 2011 Jan 14].
10. NSABP P-5, "Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery". ClinicalTrialsgov website. Available from: http://clinicaltrials.gov/ct2/show/NCT01011478. [Last accessed on 2010 Oct 18].
11. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987;47:5340-6. (Pubitemid 17152943)
12. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60. (Pubitemid 26171681)
13. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114:873-7. (Pubitemid 28217551)
14. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
15. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environmental and Molecular Mutagenesis 2004;44:26-35. (Pubitemid 38982070)
16. Hu Y, Le Leu RK, Young GP. Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer 2005;116:870-5. (Pubitemid 41209192)
17. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, Fuchs CS. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140:157-66.
18. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23. (Pubitemid 41215460)
19. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2006;15:1785-90. (Pubitemid 44664249)
20. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti inflammatory drugs-A review. Cancer 2002;94:950-63. (Pubitemid 34150849)
21. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15. (Pubitemid 47073542)
22. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous Polyposis. Gastroenterology 1991;101:635-9.
23. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis. N Engl J Med 1993;328:1313-6. (Pubitemid 23131373)
24. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized Controlled Trial of the Effect of Sulindac on Duodenal and Rectal Polyposis and Cell-Proliferation in Patients with Familial Adenomatous Polyposis. Br J Surg 1993;80:1618-9. (Pubitemid 24007679)
25. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52. (Pubitemid 30419089)
26. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-60. (Pubitemid 37323278)
27. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim KM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
28. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, et al. Effect of Celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35. (Pubitemid 44358879)
29. Fuchs C, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005;23:3530.
30. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
31. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, et al. Nonsteroidal anti-inflammatory drugs: Effects on mortality after colorectal cancer diagnosis. Cancer 2009;115:5662-71.
32. 80702 "A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX with or without celecoxib therapy for patients with stage III colon cancer". Cancer and Leukemia Group B Summer 2009 Agenda Book: Available from: http://www.calgb.org/Public/meetings/meeting-documents/2009/summer-group/ AgendaBook-062009.pdf, page 062007. [ Last accessed on 2010 Feb 1].
33. Gerner EW, Meyskens FL Jr. Polyamines and cancer: Old molecules, new understanding. Nat Rev Cancer 2004;4:781-92. (Pubitemid 39331150)
34. Meyskens FL, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, et al. Dose De-Escalation Chemoprevention Trial of Alpha- Difluoromethylornithine in Patients with Colon Polyps. J Natl Cancer Inst 1994;86:1122-30. (Pubitemid 24249297)
35. Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, et al. Effect of alpha-difluoromethylornithine on Rectal Mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8. (Pubitemid 28407087)
36. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008;1:32-8.
37. S0820, "A double-blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer." Southwest Oncology Group Fall 2009 Group Meeting Agenda. Available from: https://swog.org/Visitors/Fall09GpMtg/0910Agenda.pdf , page 0937. [Last accessed on 2010 Feb 1].